Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2Dermatologic 1

Conditions

Osteosarcoma 2Neuroblastoma 2Sarcoma 1Melanoma 1

Interventions

Cyclophosphamide 14Gemcitabine 6Filgrastim 6fludarabine 5Methotrexate 5Leucovorin 5Granulocyte Colony-Stimulating Factor 5Zoledronic Acid 4Temozolomide 4Mesna 4Irinotecan 4Ifosfamide 4Etoposide 4Cisplatin 4Carboplatin 4pembrolizumab 3fludarabine phosphate 3Doxorubicin 3Biopsy 3tanespimycin 2poly ICLC 2pegfilgrastim 2lorukafusp alfa 2liposomal doxorubicin 2dinutuximab 2cabozantinib 2belinostat 2Topotecan 2Thalidomide 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Osteosarcoma × lorukafusp alfa × Clear all
NCT03209869 2022-09-13

Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2

University of Wisconsin, Madison

Phase 1 Withdrawn
CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT00003750 2014-08-08

Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors

Children's Oncology Group

Phase 1 Completed
28 enrolled
CNSDermatologicSarcoma

Melanoma, Neuroblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡